---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-003401"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:58:31.564248+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio FY2024 net loss $42.1M; AD02 top-line data expected June 2025

## Summary
- Net loss $42.1M vs $30.0M in FY2023; R&D expenses rose to $33.2M from $20.3M.
- Cash and equivalents $20.9M as of Dec 31, 2024; $22.9M shares outstanding.
- Completed $27.5M equity offering (incl. ~3.9M warrants) and repaid Silicon Valley Bank loan.
- AD02 Phase 2 Alzheimer's trial fully enrolled (208 patients); top-line cognitive results due June 2025.
- CORDStrom planning BLA filing in RDEB in 2025/early 2026, eligible for Priority Review Voucher.

## SEC filing metadata
- accession: 0001013762-25-003401
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/0001013762-25-003401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/ea0235584-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-003401
- JSON: https://secwatch.observer/filing/0001013762-25-003401.json
- Plain text: https://secwatch.observer/filing/0001013762-25-003401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.